Beta Bionics, Inc. Common Stock (BBNX) - Net Assets
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has net assets worth $271.25 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($304.42 Million) and total liabilities ($33.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Beta Bionics, Inc. Common Stock to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $271.25 Million |
| % of Total Assets | 89.1% |
| Annual Growth Rate | 180.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 137.52 |
Beta Bionics, Inc. Common Stock - Net Assets Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Beta Bionics, Inc. Common Stock (BBNX) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual net assets of Beta Bionics, Inc. Common Stock from 2022 to 2025. For live valuation and market cap data, see market value of Beta Bionics, Inc. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $287.61 Million | +278.37% |
| 2024-12-31 | $76.01 Million | +29.70% |
| 2023-12-31 | $58.61 Million | +350.83% |
| 2022-12-31 | $13.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beta Bionics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18437200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $403.00K | 0.14% |
| Other Components | $657.14 Million | 228.48% |
| Total Equity | $287.61 Million | 100.00% |
Beta Bionics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GuangDong GenSho Logistics Co
SHG:603813
|
$587.79 Million |
|
Groupe CRIT SA
PA:CEN
|
$587.79 Million |
|
Gemtek Technology Co Ltd
TW:4906
|
$588.03 Million |
|
BELL AGROMACHINA ORD T (BSE)
NSE:BALUFORGE
|
$588.07 Million |
|
Chatham Lodging Trust REIT
NYSE:CLDT
|
$587.49 Million |
|
Movado Group Inc
NYSE:MOV
|
$587.34 Million |
|
Floridienne
BR:FLOB
|
$587.25 Million |
|
AnShan Heavy Duty Mining Machinery Co Ltd
SHE:002667
|
$587.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beta Bionics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 76,013,000 to 287,610,000, a change of 211,597,000 (278.4%).
- Net loss of 73,200,000 reduced equity.
- New share issuances of 210,117,000 increased equity.
- Other comprehensive income increased equity by 338,000.
- Other factors increased equity by 74,342,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-73.20 Million | -25.45% |
| Share Issuances | $210.12 Million | +73.06% |
| Other Comprehensive Income | $338.00K | +0.12% |
| Other Changes | $74.34 Million | +25.85% |
| Total Change | $- | 278.37% |
Book Value vs Market Value Analysis
This analysis compares Beta Bionics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.07x to 1.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $2.60 | $13.19 | x |
| 2023-12-31 | $11.05 | $13.19 | x |
| 2024-12-31 | $11.94 | $13.19 | x |
| 2025-12-31 | $7.10 | $13.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beta Bionics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -73.02%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.14x
- Recent ROE (-25.45%) is above the historical average (-167.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -498.08% | -36173.74% | 0.01x | 2.73x | $-66.05 Million |
| 2023 | -75.24% | -367.64% | 0.11x | 1.88x | $-49.96 Million |
| 2024 | -72.04% | -84.08% | 0.44x | 1.97x | $-62.36 Million |
| 2025 | -25.45% | -73.02% | 0.30x | 1.14x | $-101.96 Million |
Industry Comparison
This section compares Beta Bionics, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beta Bionics, Inc. Common Stock (BBNX) | $271.25 Million | -498.08% | 0.12x | $587.77 Million |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more